The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
